GlassScriptPhysician profile
Uzma Mehdi
NPI 1336384577
$2,910.23
in general payments reported to CMS, 2019-2025
24 companies · $975 in 2025
The $975 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $159 · 2021: $114 · 2022: $362 · 2023: $338 · 2024: $851 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163 · Education: $1.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.87 |
| Education | $1.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $503.74 | 2020-2025 | Krystexxa, Tavneos |
| Fresenius USA Marketing, INC. | $396.05 | 2020-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $369.97 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $312.48 | 2022-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $151.27 | 2021-2025 | |
| Travere Therapeutics, INC. | $121.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $116.06 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $111.68 | 2023-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $96.43 | 2019-2025 | Ultomiris |
| Glaxosmithkline, LLC. | $84.71 | 2020-2025 | Benlysta |
| Akebia Therapeutics INC | $79.94 | 2019-2025 | Vafseo |
| Novo Nordisk INC | $74.68 | 2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $71.99 | 2025 | Tarpeyo |
| Vifor Pharma, INC. | $57.87 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $57.39 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $55.77 | 2024 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.62 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $43.81 | 2022-2023 | Krystexxa |
| Scpharmaceuticals INC. | $37.97 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $30.32 | 2022-2024 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.20 | 2024 | |
| Mallinckrodt Enterprises LLC | $25.40 | 2019 | |
| Kyowa Kirin, INC. | $22.36 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $17.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Mehdi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.